Pay in 4 interest-free payments of $5.68 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Introduction Hepatocellular carcinoma (HCC) is the sixth most common cancer and the fourth leading cause of cancer-related death in the world (Ferlay et al., 2019), and its burden is expected to increase in the next few years
Once reconstituted, keep at 28 C and use within 7 days to maintain 98% peptide integrity
Tirzepatide: Dual GIP/GLP-1 receptor agonist in a single molecule
Administration: The injections are delivered intravenously, bypassing the digestive system, which ensures nearly 100% absorption of the active ingredient
US$ 29.38
US$ 22.30
.webp)
US$ 22.01
US$ 29.53
US$ 23.83
US$ 23.11
US$ 23.83
US$ 26.11
US$ 28.60
US$ 24.77
